RhumbLine Advisers’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

RhumbLine Advisers’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-303	Closed	-$12.2K	–	4217
2024 Q3	$12.2K	Buy	303 +101	+50%	+$3.98K	﹤0.01%	3866
2024 Q2	$7.87K	Buy	202 +38	+23%	+$1.04K	﹤0.01%	4017
2024 Q1	$3.55K	Hold	164	–	–	﹤0.01%	4025
2023 Q4	$4.22K	Buy	164 +15	+10%	+$281	﹤0.01%	4012
2023 Q3	$2.72K	Buy	149 +10	+7%	+$173	﹤0.01%	4077
2023 Q2	$2.18K	Buy	+139	New	+$2.93K	﹤0.01%	4207

RhumbLine Advisers's CALT Position: Q4 2024 in Review

RhumbLine Advisers sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q4 2024, closing a stake of 303 shares — an estimated $12.2K sold.

RhumbLine Advisers first reported a position in CALT in Q2 2023 and held it in 6 quarters. The position peaked at $12.2K in Q3 2024. 0 funds tracked by Wall St. Rank hold CALT as of Q4 2024.

RhumbLine Advisers reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q4 2024 after selling out during the quarter.
RhumbLine Advisers sold 303 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2024, an estimated $12.2K.
RhumbLine Advisers first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2023 and held it in 6 quarters.
RhumbLine Advisers's Calliditas Therapeutics AB American Depositary Shares position peaked at $12.2K in Q3 2024.
0 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2024.

Based on RhumbLine Advisers's 13F filing for Q4 2024, filed 30 Jan 2025.